PMID- 30855709
OWN - NLM
STAT- MEDLINE
DCOM- 20200514
LR  - 20200514
IS  - 1576-6578 (Electronic)
IS  - 0210-0010 (Linking)
VI  - 68
IP  - 6
DP  - 2019 Mar 16
TI  - [Reversible cerebral vasoconstriction syndrome associated with anastrozole: an 
      unusual cause of high impact].
PG  - 250-254
LID - 10.33588/rn.6806.2018373 [doi]
AB  - INTRODUCTION: Reversible cerebral vasoconstriction syndrome (RCVS) is a low 
      incidence disability with a multifactorial etiology and a wide array of symptoms. 
      The main symptom is a thunderclap headache, accompanied sometimes with various 
      neurological deficits that can lead to death. RCVS is usually diagnosed through 
      radiological imaging technology. The treatment includes adopting general measures 
      of monitoring, symptomatic management, identifying the etiology and acting on it 
      to avoid recurrence. CASE REPORT: A 71-year-old woman with a history of breast 
      cancer originally treated with tamoxifen. Due to urticaria, the anastrozole 
      management was staggered. She was admitted for aphasia, drowsiness and a 
      thunderclap headache. The patient reported a similar event two weeks prior 
      admission. In brain resonance, there was evidence of small sub-arachnoidal 
      haemorrhage (SAH) of the left parietal temporal convexity and cerebral 
      angiography. As well as documented vasospasm in the posterior parietal region 
      confirming the diagnosis of RCVS plus SAH. During the stay, she presented three 
      events with the same characteristics, requiring intensive monitoring and two 
      therapeutic panangiographies with intra-arterial nimodipine with subsequent 
      resolution of the vessel spasm. The patient remains asymptomatic six months 
      later. CONCLUSION: RCVS is difficult to diagnose given its wide array of symptoms 
      and multifactorial etiology. In this case, RCVS plus SAH is associated with the 
      use of anastrozole. So far there are no reported cases of aromatase inhibitors 
      associated with this pathology and should be reported in the literature for 
      pharmacovigilance.
FAU - Coral-Casas, J
AU  - Coral-Casas J
AD  - Pontificia Universidad Javeriana, Bogota DC, Colombia.
FAU - Ricaurte-Fajardo, A
AU  - Ricaurte-Fajardo A
AD  - Pontificia Universidad Javeriana, Bogota DC, Colombia.
FAU - McCormick, S J
AU  - McCormick SJ
AD  - Pontificia Universidad Javeriana, Bogota DC, Colombia.
FAU - Baracaldo, I
AU  - Baracaldo I
AD  - Pontificia Universidad Javeriana, Bogota DC, Colombia.
FAU - Jimenez, C A
AU  - Jimenez CA
AD  - Pontificia Universidad Javeriana, Bogota DC, Colombia.
FAU - Mejia, J A
AU  - Mejia JA
AD  - Pontificia Universidad Javeriana, Bogota DC, Colombia.
LA  - spa
PT  - Case Reports
PT  - Journal Article
TT  - Sindrome de vasoconstriccion cerebral reversible asociado a anastrozol: una causa 
      inusual de alto impacto.
PL  - Spain
TA  - Rev Neurol
JT  - Revista de neurologia
JID - 7706841
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 2Z07MYW1AZ (Anastrozole)
SB  - IM
MH  - Aged
MH  - Anastrozole/*adverse effects
MH  - Antineoplastic Agents, Hormonal/*adverse effects
MH  - Cerebrovascular Disorders/*chemically induced
MH  - Female
MH  - Humans
MH  - Syndrome
MH  - Vasoconstriction
EDAT- 2019/03/12 06:00
MHDA- 2020/05/15 06:00
CRDT- 2019/03/12 06:00
PHST- 2019/03/12 06:00 [entrez]
PHST- 2019/03/12 06:00 [pubmed]
PHST- 2020/05/15 06:00 [medline]
AID - rn2018373 [pii]
AID - 10.33588/rn.6806.2018373 [doi]
PST - ppublish
SO  - Rev Neurol. 2019 Mar 16;68(6):250-254. doi: 10.33588/rn.6806.2018373.